Targeted Therapy

CHICAGO — David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, talked about two presentations on molecular targeted therapy from the ASCO Annual Meeting.

CHICAGO — In a video interview, Healio spoke with David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, about using targeted therapy in patients with myelodysplastic syndrome at ASCO Annual Meeting.

NEW ORLEANS — There is no single answer when it comes to determining the primary target for treating type 2 diabetes, two speakers said during a debate at the American Diabetes Association Scientific Sessions.

Liquid biopsy — once just a promising technology — is now an important tool for selecting treatment for certain patients with breast cancer, according to Melissa McShane, MD.

In this video, Debu Tripathy, MD, discussed developments in HER2-positive breast cancer targeted treatments, including antibody-drug conjugates, which were reviewed at 39th Miami Breast Cancer Conference.

In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses new research into targeting protein degradation.

Targeted therapies in HER2-positive breast cancer are integral to the success of treatment outcomes in this patient population.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the clinical implications of the BEAT-AML trial and genetic testing in AML.

Healio spoke with Debu Tripathy, MD, about the use of targeted therapies in breast cancer.

Healio spoke with Debu Tripathy, MD, about treatments being developed for breast cancer.